A phase 2 study of ibrutinib as neoadjuvant therapy in patients with localized prostate cancer. Predicted probability of csPCa at biopsy.

Update from the PSMA-dRT trial: A randomized phase III trial of PSMA-PET prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer. Test results of patients ...

CLEVELAND--(BUSINESS WIRE)--Cleveland Diagnostics, Inc., a commercial-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced today two ...

Cleveland Diagnostics said Monday it received Food and Drug Administration approval for a test that analyzes the structure of protein biomarkers in the blood for prostate cancer signals, to aid in ...

In tandem with September’s Prostate Cancer Awareness Month, Cleveland Diagnostics is kicking off a campaign to boost awareness of and education around screening tests for the disease. The flagship ...

About 1 in 8 men will be diagnosed with prostate cancer in their lifetime, but the screening process for this relatively common cancer isn’t always straightforward. Diagnosis can be a drawn-out and ...